GSK1265744 Demonstrates Robust in Vitro Activity Against Various Clades of HIV-1

Overview

Journal J Acquir Immune Defic Syndr

Specialty Infectious Diseases

Date 2014 Dec 4

PMID 25469523

Citations 14

Authors

Sharon L Karmon

Hiroshi Mohri

William Spreen

Martin Markowitz

Affiliations

Soon will be listed here.

Citing Articles

Long-Acting Injectable Antiretroviral Agents for HIV Treatment and Prevention.

Kim Y Infect Chemother. 2022; 53(4):686-695.

PMID: 34979604 PMC: 8731252. DOI: 10.3947/ic.2021.0136.

Quantum Mechanical-Based Stability Evaluation of Crystal Structures for HIV-Targeted Drug Cabotegravir.

Han Y, Luo H, Lu Q, Liu Z, Liu J, Zhang J Molecules. 2021; 26(23).

PMID: 34885762 PMC: 8659202. DOI: 10.3390/molecules26237178.

Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis.

Cutrell A, Schapiro J, Perno C, Kuritzkes D, Quercia R, Patel P AIDS. 2021; 35(9):1333-1342.

PMID: 33730748 PMC: 8270504. DOI: 10.1097/QAD.0000000000002883.

Identification of Novel UGT1A1 Variants Including UGT1A1 454C>A through the Genotyping of Healthy Participants of the HPTN 077 Study.

Seneviratne H, Hamlin A, Li S, Grinsztejn B, Dawood H, Liu A ACS Pharmacol Transl Sci. 2021; 4(1):226-239.

PMID: 33615175 PMC: 7888308. DOI: 10.1021/acsptsci.0c00181.

Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults.

Letendre S, Mills A, Hagins D, Swindells S, Felizarta F, Devente J J Antimicrob Chemother. 2019; 75(3):648-655.

PMID: 31873746 PMC: 7021098. DOI: 10.1093/jac/dkz504.

References

Plosker G . Emtricitabine/tenofovir disoproxil fumarate: a review of its use in HIV-1 pre-exposure prophylaxis. Drugs. 2013; 73(3):279-91. DOI: 10.1007/s40265-013-0024-4. View

Spreen W, Margolis D, Pottage Jr J . Long-acting injectable antiretrovirals for HIV treatment and prevention. Curr Opin HIV AIDS. 2013; 8(6):565-71. PMC: 3815009. DOI: 10.1097/COH.0000000000000002. View

Andrews C, Spreen W, Mohri H, Moss L, Ford S, Gettie A . Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus. Science. 2014; 343(6175):1151-4. PMC: 4308974. DOI: 10.1126/science.1248707. View

Markowitz M, Evering T, Garmon D, Caskey M, La Mar M, Rodriguez K . A randomized open-label study of 3- versus 5-drug combination antiretroviral therapy in newly HIV-1-infected individuals. J Acquir Immune Defic Syndr. 2014; 66(2):140-7. PMC: 4123437. DOI: 10.1097/QAI.0000000000000111. View

Reuman E, Bachmann M, Varghese V, Fessel W, Shafer R . Panel of prototypical raltegravir-resistant infectious molecular clones in a novel integrase-deleted cloning vector. Antimicrob Agents Chemother. 2009; 54(2):934-6. PMC: 2812164. DOI: 10.1128/AAC.01345-09. View

Grant R, Lama J, Anderson P, McMahan V, Liu A, Vargas L . Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363(27):2587-99. PMC: 3079639. DOI: 10.1056/NEJMoa1011205. View

Mohammed K, Topper M, Muesing M . Sequential deletion of the integrase (Gag-Pol) carboxyl terminus reveals distinct phenotypic classes of defective HIV-1. J Virol. 2011; 85(10):4654-66. PMC: 3126176. DOI: 10.1128/JVI.02374-10. View

Roehr B . FDA approves first drug to prevent HIV infection. BMJ. 2012; 345:e4879. DOI: 10.1136/bmj.e4879. View

Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S . Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012; 367(5):411-22. PMC: 3687217. DOI: 10.1056/NEJMoa1202614. View

10.

Rolland M, Edlefsen P, Larsen B, Tovanabutra S, Sanders-Buell E, Hertz T . Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature. 2012; 490(7420):417-20. PMC: 3551291. DOI: 10.1038/nature11519. View

11.

Baalwa J, Wang S, Parrish N, Decker J, Keele B, Learn G . Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones. Virology. 2012; 436(1):33-48. PMC: 3545109. DOI: 10.1016/j.virol.2012.10.009. View

12.

Salazar-Gonzalez J, Salazar M, Keele B, Learn G, Giorgi E, Li H . Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med. 2009; 206(6):1273-89. PMC: 2715054. DOI: 10.1084/jem.20090378. View

13.

Low A, Prada N, Topper M, Vaida F, Castor D, Mohri H . Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors. Antimicrob Agents Chemother. 2009; 53(10):4275-82. PMC: 2764199. DOI: 10.1128/AAC.00397-09. View